No Data
Painful Week for Individual Investors Invested in Exscientia Plc (NASDAQ:EXAI) After 12% Drop, Institutions Also Suffered Losses
Key Insights The considerable ownership by individual investors in Exscientia indicates that they collectively have a greater say in management and business strategy A total of 6 investors have a ma
Germany's Merck Bets on AI Drug-Design Partnerships, Rules Out Acquisitions - Interview
By Helena Smolak and Stefanie Haxel Germany's Merck KGaA is betting on artificial-intelligence partnerships to develop new drugs, but refraining from bringing in external expertise through acquisitio
Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology
— AI drug design pioneer John P. Overington, Ph.D., appointed to Chief Technology Officer to maximise strategic technology integration and application — — Maria-Louise Fjällskog, M.D., Ph.D., appointed interim Chief
Can Exscientia (EXAI) Climb 57.17% to Reach the Level Wall Street Analysts Expect?
Exscientia to Present at Upcoming Investor Conferences in June
Exscientia plc (NASDAQ:EXAI) today announced that members of Exscientia management will participate in the following upcoming investor conferences in June: Barclays Digital and Disruptive Technology Conference. Panel
Analysts Are Upgrading Exscientia Plc (NASDAQ:EXAI) After Its Latest Results